An update after 16 years of hepatitis B vaccination in South Africa (Q38039617)

27 August 2017

An update after 16 years of hepatitis B vaccination in South Africa (English)

1 reference

27 August 2017

0 references

1 reference

2

Anna Kramvis

0 references

Rosemary J Burnett

object named as

Rosemary J Burnett

series ordinal

1

0 references

author name string

Carine Dochez

series ordinal

3

1 reference

PubMed ID

22939021

27 August 2017

André Meheus

series ordinal

4

1 reference

PubMed ID

22939021

27 August 2017

language of work or name

English

0 references

publication date

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

30 Suppl 3

1 reference

27 August 2017

C45-51

1 reference

Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Postnatal infectivity of hepatitis B surface antigen-carrier mothers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B and pregnancy: an underestimated issue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Immune tolerance split between hepatitis B virus precore and core proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B epidemiology in Asia, the Middle East and Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Horizontal transmission of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B virus DNA in saliva from children with chronic hepatitis B infection: implications for saliva as a potential mode of horizontal transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B vaccination: how to reach risk groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B vaccination coverage in healthcare workers in Gauteng Province, South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Boosters for hepatitis B. European Consensus Group on Hepatitis B Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B vaccine -- do we need boosters?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

The decision making process on new vaccines introduction in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Implementing a birth dose of hepatitis B vaccine for home deliveries in Africa--too soon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B infection among health workers in Uganda: evidence of the need for health worker protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Vaccination against hepatitis B in health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

European survey of hepatitis B vaccination policies for healthcare workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Viral hepatitis in South African healthcare workers at increased risk of occupational exposure to blood-borne viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

How AIDS forces reappraisal of hepatitis B virus control in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Malignant liver tumors in South African children: a national audit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Combination vaccines in the South African setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.021

10.1016/J.VACCINE.2012.02.021

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22939021